These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37093125)

  • 21. Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.
    Narayanan P; Curtis BR; Shen L; Schneider E; Tami JA; Paz S; Burel SA; Tai LJ; Machemer T; Kwoh TJ; Xia S; Shattil SJ; Witztum JL; Engelhardt JA; Henry SP; Monia BP; Hughes SG
    Nucleic Acid Ther; 2020 Apr; 30(2):94-103. PubMed ID: 32043907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88.
    Senn JJ; Burel S; Henry SP
    J Pharmacol Exp Ther; 2005 Sep; 314(3):972-9. PubMed ID: 15919763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.
    Henry SP; Bolte H; Auletta C; Kornbrust DJ
    Toxicology; 1997 Jun; 120(2):145-55. PubMed ID: 9184201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in platelet immunoprotein levels during therapy in adult immune thrombocytopenia.
    Ball S; Zuiable A; Roter BL; Hegde UM
    Br J Haematol; 1985 Aug; 60(4):631-3. PubMed ID: 3875364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide.
    Grossman TR; Carrer M; Shen L; Johnson RB; Hettrick LA; Henry SP; Monia BP; McCaleb ML
    Mol Vis; 2017; 23():561-571. PubMed ID: 28855795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes.
    Baldwin WM; Samaniego-Picota M; Kasper EK; Clark AM; Czader M; Rohde C; Zachary AA; Sanfilippo F; Hruban RH
    Transplantation; 1999 Sep; 68(6):894-900. PubMed ID: 10515392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense oligonucleotides and nucleic acids generate hypersensitive platelets.
    Zaslavsky A; Adams M; Cao X; Yamaguchi A; Henderson J; Busch-Østergren P; Udager A; Pitchiaya S; Tourdot B; Kasputis T; Church SJ; Lee SK; Ohl S; Patel S; Morgan TM; Alva A; Wakefield TW; Reichert Z; Holinstat M; Palapattu GS
    Thromb Res; 2021 Apr; 200():64-71. PubMed ID: 33540294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
    Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
    Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
    Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
    Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
    J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced shear-induced platelet aggregation due to low-temperature storage.
    Montgomery RK; Reddoch KM; Evani SJ; Cap AP; Ramasubramanian AK
    Transfusion; 2013 Jul; 53(7):1520-30. PubMed ID: 23043289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by complement and phagocytes in the presence of HLA antibodies.
    Meinke S; Sandgren P; Mörtberg A; Karlström C; Kadri N; Wikman A; Höglund P
    Transfusion; 2016 Feb; 56(2):370-82; quiz 369. PubMed ID: 26442787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local and systemic tolerability of a 2'O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey.
    Fey RA; Templin MV; McDonald JD; Yu RZ; Hutt JA; Gigliotti AP; Henry SP; Reed MD
    Inhal Toxicol; 2014 Jul; 26(8):452-63. PubMed ID: 24932560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
    Mirlashari MR; Vetlesen A; Nissen-Meyer LSH; Naper C; Tjønnfjord GE; Njerve IU; Ezligini F; Landmark BF; Meinke S; Sandgren P; Höglund P; Hetland G
    Transfusion; 2021 Apr; 61(4):1222-1234. PubMed ID: 33580979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unexpected thrombocytopenia and anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody.
    Everds N; Li N; Bailey K; Fort M; Stevenson R; Jawando R; Salyers K; Jawa V; Narayanan P; Stevens E; He C; Nguyen MP; Tran S; Doyle N; Poitout-Belissent F; Jolette J; Xu C; Sprugel K
    Toxicol Pathol; 2013; 41(7):951-69. PubMed ID: 23475561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The induction of interleukin-6 (IL-6) and colony-stimulating factors (CSFs) by FK565 and its thrombopoietic activity following in vivo administration.
    Maeda M; Suzuki S; Ohtsuka K; Satoh S; Nishigaki F; Shimomura K; Imai Y; Niwa M; Kohsaka M
    Biol Pharm Bull; 1994 Feb; 17(2):173-9. PubMed ID: 7515742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased atherosclerosis and glomerulonephritis in cynomolgus monkeys (Macaca fascicularis) given injections of BSA over an extended period of time.
    Stills HF; Bullock BC; Clarkson TB
    Am J Pathol; 1983 Nov; 113(2):222-34. PubMed ID: 6227252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of idiopathic thrombocytopenic purpura patients with antiglycoprotein IIb/IIIa or Ib autoantibodies.
    Nomura S; Yanabu M; Soga T; Kido H; Fukuroi T; Yamaguchi K; Nagata H; Kokawa T; Yasunaga K
    Acta Haematol; 1991; 86(1):25-30. PubMed ID: 1950358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human platelet antigen (HPA)-specific immunoglobulin M antibodies in neonatal alloimmune thrombocytopenia can inhibit the binding of HPA-specific immunoglobulin G antibodies.
    Hopkins M; Lucas G; Calvert A; Bendukidze N; Green F; Kotecha K; Poles A
    Transfusion; 2017 May; 57(5):1267-1271. PubMed ID: 28236317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense oligonucleotide targeting of thrombopoietin represents a novel platelet depletion method to assess the immunomodulatory role of platelets.
    Barrett TJ; Wu BG; Revenko AS; MacLeod AR; Segal LN; Berger JS
    J Thromb Haemost; 2020 Jul; 18(7):1773-1782. PubMed ID: 32227586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.